ArriVent BioPharma, Inc. AVBP Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -55.2%+3.7pp | -58.9%-6.9pp | -52%-1.9pp | -50.1%-1.1pp | -49%— | |
| Return on invested capital | -75.6%+4.2pp | -79.7%— | —— | —— | -183%— | |
| Liquidity | ||||||
| Current ratio | 14×+1.1× | 12.8×-2.1× | 14.9×+2.2× | 12.7×-1.6× | 14.3×+1.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×— | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $7.19-10.0% | $7.99+9.8% | $7.28+1.9% | $7.14+19.5% | $5.97-27.0% | |
| Valuation | ||||||
| Market capitalization | $1.02B+22.8% | $830.58M+11.0% | $748.5M-5.3% | $790.65M+25.7% | $628.96M-29.9% | |
| Price / book | 3.1×+0.4× | 2.7×+0.2× | 2.5×-0.7× | 3.2×+0.1× | 3.1×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do ArriVent BioPharma, Inc.'s ratios come from?
- Every ratio is computed from ArriVent BioPharma, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.